๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

โœ Scribed by Gandhi, L.; Camidge, D. R.; Ribeiro de Oliveira, M.; Bonomi, P.; Gandara, D.; Khaira, D.; Hann, C. L.; McKeegan, E. M.; Litvinovich, E.; Hemken, P. M.; Dive, C.; Enschede, S. H.; Nolan, C.; Chiu, Y.-L.; Busman, T.; Xiong, H.; Krivoshik, A. P.; Humerickhouse, R.; Shapiro, G. I.; Rudin, C. M.

Book ID
121876785
Publisher
American Society of Clinical Oncology
Year
2011
Tongue
English
Weight
299 KB
Volume
29
Category
Article
ISSN
0732-183X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase I Study of Navitoclax (ABT-263), a
Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
โœ Gandhi, L.; Camidge, D. R.; Ribeiro de Oliveira, M.; Bonomi, P.; Gandara, D.; Kh ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› American Society of Clinical Oncology ๐ŸŒ English โš– 299 KB

## Purpose Resistance to chemotherapy-induced apoptosis represents a major obstacle to cancer control. Overexpression of Bcl-2 is seen in multiple tumor types and targeting Bcl-2 may provide therapeutic benefit. A phase I study of navitoclax, a novel inhibitor of Bcl-2 family proteins, was conduct